

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Final draft guidance**

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

The company consultation response noted that not recommending ripretinib may have indirect equality implications including inequalities in access by geography and specialist centres, disproportionate impact on a rare, high-need population in which it is difficult to generate clinical evidence, and mental health and caregiver burden due to psychological distress for patients and carers.

Stakeholder responses noted ripretinib availability in Scotland but not in England and Wales, creating an unjust disparity in access to a life-extending treatment within the UK.

The committee discussed potential equality issues raised by stakeholders but agreed that these were either not equality issues or could not be addressed in a NICE technology evaluation. The recommendation does not restrict access to some people over others.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups?

If so, what are the barriers to, or difficulties with, access for the specific group?
No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes, in section 3.17.

**Approved by Principal Technical Adviser (name):** Elizabeth Bell

**Date:** 20<sup>th</sup> March 2026